Next Article in Journal
Impact of Erythropoietin Production by Erythroblastic Island Macrophages on Homeostatic Murine Erythropoiesis
Next Article in Special Issue
Bacterial Persister-Cells and Spores in the Food Chain: Their Potential Inactivation by Antimicrobial Peptides (AMPs)
Previous Article in Journal
The Immune Endocannabinoid System of the Tumor Microenvironment
Previous Article in Special Issue
Role of Bioactive Peptide Sequences in the Potential Impact of Dairy Protein Intake on Metabolic Health
Article

Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors’ Activation

Department of Respiration Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-105 Warsaw, Poland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(23), 8931; https://doi.org/10.3390/ijms21238931
Received: 26 October 2020 / Revised: 23 November 2020 / Accepted: 24 November 2020 / Published: 25 November 2020
(This article belongs to the Special Issue Peptides for Health Benefits 2020)
The opioid-induced analgesia is associated with a number of side effects such as addiction, tolerance and respiratory depression. The involvement of neuropeptide FF (NPFF) in modulation of pain perception, opioid-induced tolerance and dependence was well documented in contrast to respiratory depression. Therefore, the aim of the present study was to examine the potency of NPFF to block post-opioid respiratory depression, one of the main adverse effects of opioid therapy. Urethane-chloralose anaesthetized Wistar rats were injected either intravenously (iv) or intracerebroventricularly (icv) with various doses of NPFF prior to iv endomorphin-1 (EM-1) administration. Iv NPFF diminished the number of EM-1-induced apneas without affecting their length and without influence on the EM-1 induced blood pressure decline. Icv pretreatment with NPFF abolished the occurrence of post-EM-1 apneas and reduced also the maximal drop in blood pressure and heart rate. These effects were completely blocked by the NPFF receptor antagonist RF9, which was given as a mixture with NPFF before systemic EM-1 administration. In conclusion, our results showed that centrally administered neuropeptide FF is effective in preventing apnea evoked by stimulation of μ-opioid receptors and the effect was due to activation of central NPFF receptors. Our finding indicates a potential target for reversal of opioid-induced respiratory depression. View Full-Text
Keywords: neuropeptide FF; NPFF receptors; μ-opioid receptors; endomorphin-1; apnea neuropeptide FF; NPFF receptors; μ-opioid receptors; endomorphin-1; apnea
Show Figures

Graphical abstract

MDPI and ACS Style

Wojciechowski, P.; Andrzejewski, K.; Kaczyńska, K. Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors’ Activation. Int. J. Mol. Sci. 2020, 21, 8931. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21238931

AMA Style

Wojciechowski P, Andrzejewski K, Kaczyńska K. Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors’ Activation. International Journal of Molecular Sciences. 2020; 21(23):8931. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21238931

Chicago/Turabian Style

Wojciechowski, Piotr, Kryspin Andrzejewski, and Katarzyna Kaczyńska. 2020. "Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors’ Activation" International Journal of Molecular Sciences 21, no. 23: 8931. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21238931

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop